ESC 365 - Evaluating cardiovascular risk reduction with glucagon-like peptide-1 receptor agonists.

Open Access

Evaluating cardiovascular risk reduction with glucagon-like peptide-1 receptor agonists.

Session: Discussing clinical implications of glucagon-like peptide-1 receptor agonists

Topic: Pharmacotherapy

Speaker: Doctor M. Lehrke (Aachen, DE)

Sponsored by Novo Nordisk A/S

Event: ESC Congress 2020

Congress Presentation

Add to my library

About the speaker

Doctor Michael Lehrke

RWTH University Hospital Aachen, Aachen (Germany)

0 follower

4 more presentations in this session

Welcome and introduction.

Speaker: Professor K. Connelly (Toronto, CA)

Highlighting cardiovascular benefits of glucagon-like peptide-1 receptor agonists.

Speaker: Professor K. Connelly (Toronto, CA)

Exploring the gap between data and clinical practice.

Speaker: Assistant Professor N. Pagidipati (Durham, US)

Panel discussion.

Speaker: Professor K. Connelly (Toronto, CA) Doctor M. Lehrke (Aachen, DE) Assistant Professor N. Pagidipati (Durham, US)

Access the full session

Discussing clinical implications of glucagon-like peptide-1 receptor agonists

Speakers: Doctor M. Lehrke, Professor K. Connelly, Professor K. Connelly, Assistant Professor N. Pagidipati, Professor K. Connelly...

About the event

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources